Cell culture compositions with antioxidants and methods for polypeptide production

What is this patent about?

’732 is related to the field of cell culture manufacturing and the production of protein-based products, such as therapeutic antibodies. In commercial bioprocessing, optimizing media to improve productivity often leads to undesirable quality attributes, specifically an increase in the color intensity of the final protein product. This phenomenon is particularly problematic in high-concentration liquid formulations required for subcutaneous delivery, where oxidation of reactive amino acid residues can compromise regulatory compliance and product consistency.

The underlying idea behind ’732 is the use of specific antioxidant compounds within the cell culture medium to suppress the chemical pathways that lead to protein coloration during the growth and production phases. By identifying that certain reactive oxygen species and metabolic by-products contribute to the darkening of the polypeptide composition, the invention introduces targeted additives that stabilize the protein without negatively impacting cell viability or overall yield. This approach shifts the focus from post-production purification to upstream prevention of oxidative degradation.

The claims of ’732 focus on a method for producing a recombinant polypeptide composition with reduced color intensity by incorporating aminoguanidine into the cell culture medium. The process involves culturing a cell containing the relevant genetic instructions in this specialized medium to produce the polypeptide. The presence of aminoguanidine is specifically defined by its functional ability to result in a final protein composition that is lighter in color compared to one produced using standard media lacking this additive.

In practice, the invention is implemented by supplementing either basal or feed media with aminoguanidine at concentrations typically ranging from 0.0003 mM to 10 mM. During the 14-day culture cycle of Chinese Hamster Ovary (CHO) cells, the additive works to neutralize precursors of color-forming variants. The resulting protein is then recovered through standard affinity chromatography, yielding a concentrated drug substance that appears as a colorless or only slightly colored liquid, even at concentrations exceeding 100 mg/mL.

This invention differs from prior approaches that relied heavily on downstream purification steps to remove colored variants, which often resulted in lower product recovery and higher costs. By utilizing a chemically defined additive like aminoguanidine, the method provides a predictable and scalable solution to color issues. Unlike other antioxidants that may interfere with cell growth or fail to address specific oxidative pathways, this targeted media supplementation maintains high antibody titers while ensuring the final product meets strict aesthetic and quality standards for human therapeutic use.